We are doing this study to test a behavioral lifestyle program designed specifically for adolescent and young adult cancer survivors. Study participants will use a smartphone app and Fitbit activity tracker to help them develop healthier habits.

Have you been diagnosed with B-cell post-transplant lymphoproliferative disorder (PTLD) after an organ transplant? Have you not yet received any type of treatment for this condition? Then you may be eligible for a study to look at the safety and effectiveness of tafasitamab and rituximab combination treatment for PTLD.

This study is being done to answer the following question: What are the effects (good or bad) of adding a study drug (duvelisib or CC-486 (azacitidine)) to the usual combination of drugs? We are doing this study because we want to find out if this approach is better or worse than the usual approach for T-cell lymphoma. The usual approach is defined as care most people get for peripheral T-cell lymphoma.

To evaluate whether early drug treatment extends overall survival compared with delayed drug treatment with high-risk (chronic lymphocytic leukemia [CLL] newly diagnosed asymptomatic CLL/SLL patients.

Have you been diagnosed with primary central nervous system (CNS) lymphoma? If so you may be able to take part in a research study looking at whether using the study drugs lenalidomide, and nivolumab can be safely used in addition to the standard treatment of primary CNS lymphoma, and which dose is the most adequate when they are used together.

The purpose of this study is to test whether giving the study drug acalabrutinib is safe and could help control B-cell Non-Hodgkin CNS lymphoma that have not gone away, or have come back, after the first round of treatment.

The purpose of this research study is to deliver 6 months of 1:1 health coaching to cancer patients being treated at UNC Cancer Hospital. This program hopes to improve patient's self-confidence and satisfaction with how they feel and what they are able to do day-to-day. This includes exercising, support for healthy eating, emotional and social needs. Health coaching means you will receive weekly phone calls and emails from a trained coach.

Do you have Peripheral T Cell Lymphoma? Has your cancer come back or did it not get better with the last treatment you were given? If so, you may be eligible to participate in this gene therapy research study to learn more about using your own modified immune cells as possible treatment.

Researchers are studying different doses of a therapy (CD19 CAR T-cells) to find the dose that is both the most effective and the safest for patients with relapsed or refractory B-cell lymphoma.

The purpose of this study is to establish a safe dose of study cells (ATLCAR.CD30.CCR4 and ATLCAR.CD30) to give to patients with CD30+ refractory/relapsed Hodgkin's Lymphoma and Cutaneous T-Cell Lymphoma.